TC
PCRX icon

Truvestments Capital’s Pacira BioSciences PCRX Stock Holding History

Truvestments Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-33
Closed -$1.27K – 879
2022
Q4 		$1.27K Hold
33
– – ﹤0.01% 803
2022
Q3 		$2K Hold
33
– – ﹤0.01% 565
2022
Q2 		$2K Buy
+33
New +$2.16K ﹤0.01% 570

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Truvestments Capital's PCRX Position: Q1 2023 in Review

Truvestments Capital sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 33 shares — an estimated $1.27K sold.

Truvestments Capital first reported a position in PCRX in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

  • Truvestments Capital reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
  • Truvestments Capital sold 33 Pacira BioSciences shares in Q1 2023, an estimated $1.27K.
  • Truvestments Capital first reported a position in Pacira BioSciences in Q2 2022 and held it in 3 quarters.
  • Truvestments Capital's Pacira BioSciences position peaked at $2K in Q3 2022.
  • 267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Truvestments Capital's 13F filing for Q1 2023, filed 12 May 2023.